Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.
CONCLUSIONS: According to the results of this analysis, DAPT might have to be cautiously be used following PCI in a population of patients with thrombocytopenia at baseline due to the significantly higher bleeding rate including gastro-intestinal, intra-cranial bleeding and hemorrhagic stroke. Hence, special care might have to be taken when considering anti-platelet agents following PCI in these high risk patients. However, considering the present limitations of this analysis, this hypothesis will have to be confirmed in future trials.
PMID: 32334636 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Coronary Angioplasty | Drugs & Pharmacology | Gastroenterology | Heart | Hemorrhagic Stroke | Percutaneous Coronary Intervention | Statistics | Stroke | Study | Thrombocytopenia | Thrombosis | Toxicology